Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 4:49 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 769–792 of 1,800 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Brain and Central Nervous System Tumors Clear all
Completed Phase 1 Interventional

Brachytherapy in Treating Patients With Recurrent Malignant Glioma

NCT00045474
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
adjuvant therapy, iodine I 125
Procedure · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
9
States / cities
Birmingham, Alabama • Tampa, Florida • Atlanta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2009 · Synced Oct 15, 2026, 4:49 AM EDT
Completed Phase 1 Interventional

A Phase I Trial Using Combination Irinotecan and Thalidomide for Recurrent CNS Tumors

NCT00251797
View directory record Official record
Conditions
Brain and Nervous System, Cancer
Interventions
Irinotecan, Thalidomide
Drug
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2006
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Jan 7, 2010 · Synced Oct 15, 2026, 4:49 AM EDT
Completed Phase 2 Interventional

Nivolumab and Ipilimumab in People With Aggressive Pituitary Tumors

NCT04042753
View directory record Official record
Conditions
Pituitary, Pituitary Tumor, Pituitary Carcinoma, Pituitary Cancer
Interventions
Ipilimumab, Nivolumab
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
8
States / cities
Los Angeles, California • Basking Ridge, New Jersey • Middletown, New Jersey + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Oct 15, 2026, 4:49 AM EDT
Not yet recruiting Phase 2 Interventional

Neoadjuvant Pembrolizumab and Porustobart in Resectable pMMR/MSS Colon Cancer

NCT07808151
View directory record Official record
Conditions
Colon Cancer, Microsatellite Stable (MSS) Colon Cancer, Proficient Mismatch Repair (pMMR) Colon Cancer
Interventions
Pembrolizumab, Porustobart
Drug
Lead sponsor
Solstice Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
11
States / cities
Los Angeles, California • Tampa, Florida • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 15, 2026, 4:49 AM EDT
Completed Not applicable Interventional Results available

Managing Cancer and Living Meaningfully (CALM) Therapy in Individuals Diagnosed With a Primary Brain Tumor

NCT04852302
View directory record Official record
Conditions
Depression
Interventions
Cancer and Living Meaningfully (CALM) Therapy
Behavioral
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 31, 2025 · Synced Oct 15, 2026, 4:49 AM EDT
Terminated Phase 1 Interventional

Ph I Study of Lithium During Whole Brain Radiotherapy For Patients With Brain Metastases

NCT00469937
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Cognitive/Functional Effects, Neurotoxicity, Solid Tumor
Interventions
lithium carbonate, cognitive assessment, quality-of-life assessment, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
3
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 28, 2012 · Synced Oct 15, 2026, 4:49 AM EDT
Recruiting Phase 4 Interventional

Brain [18F]-FES PET/CT in Patients With Estrogen-Receptor Positive Breast Cancer

NCT06072807
View directory record Official record
Conditions
Breast Cancer, Brain Metastases
Interventions
Brain Imaging with 18F-FES
Diagnostic Test
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 24, 2025 · Synced Oct 15, 2026, 4:49 AM EDT
Completed No phase listed Observational

Rhinological Outcomes in Endonasal Pituitary Surgery

NCT01504399
View directory record Official record
Conditions
Pituitary Neoplasm, Pituitary Adenoma, Prolactinoma, Cushings Disease, Acromegaly
Interventions
Not listed
Lead sponsor
St. Joseph's Hospital and Medical Center, Phoenix
Other
Eligibility
18 Years to 80 Years
Enrollment
235 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
4
States / cities
Phoenix, Arizona • Santa Monica, California • Chicago, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 22, 2018 · Synced Oct 15, 2026, 4:49 AM EDT
Completed Phase 2 Interventional

Childhood Hypertonia of Central Origin: A Trial of Anticholinergic Treatment Effects

NCT00122044
View directory record Official record
Conditions
Dystonia
Interventions
trihexyphenidyl
Drug
Lead sponsor
University of Southern California
Other
Eligibility
5 Years to 17 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
7
States / cities
Birmingham, Alabama • Stanford, California • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated May 23, 2014 · Synced Oct 15, 2026, 4:49 AM EDT
Suspended Phase 1 Interventional

Laparoscopically Harvested Omental Free Tissue Autograft to Bypass the Blood Brain Barrier (BBB) in Human Recurrent Glioblastoma Multiforme (rGBM)

NCT04222309
View directory record Official record
Conditions
Glioma, Glioma, Malignant, Glioblastoma, Glioblastoma Multiforme, Glioblastoma Multiforme of Brain, GBM, Brain Cancer
Interventions
Laparoscopically harvested omental free flap
Procedure
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Oct 15, 2026, 4:49 AM EDT
Completed Phase 1 Interventional

Ph I Gleevec in Combo w RAD001 + Hydroxyurea for Pts w Recurrent MG

NCT00613132
View directory record Official record
Conditions
Glioblastoma, Gliosarcoma
Interventions
Gleevec, RAD001, and Hydroxyurea
Drug
Lead sponsor
Annick Desjardins
Other
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 20, 2013 · Synced Oct 15, 2026, 4:49 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Bortezomib and Temozolomide in Treating Patients With Advanced Refractory Solid Tumors or Melanoma

NCT00512798
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Melanoma, Solid Tumor
Interventions
PS-341 (VELCADE), Temozolomide, immunoenzyme technique
Drug · Other
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 2, 2012 · Synced Oct 15, 2026, 4:49 AM EDT
Terminated Phase 1 Interventional

S0114 Vaccine Therapy in Treating Patients With Gastric, Prostate, or Ovarian Cancer

NCT00023634
View directory record Official record
Conditions
Brain Tumors, Gastric Cancer, Ovarian Cancer, Prostate Cancer
Interventions
KLH, GMCSF
Biological
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years to 80 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2008
U.S. locations
13
States / cities
Bay City, Michigan • Port Huron, Michigan • Bellingham, Washington + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2015 · Synced Oct 15, 2026, 4:49 AM EDT
Completed Phase 1 Interventional

Vaccine Therapy and Sargramostim in Treating Patients With Sarcoma or Brain Tumor

NCT00069940
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Gastrointestinal Stromal Tumor, Sarcoma
Interventions
sargramostim, telomerase: 540-548 peptide vaccine
Biological
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
2 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2008
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 28, 2010 · Synced Oct 15, 2026, 4:49 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Feasibility and Clinically Application of Magnetic Resonance Fingerprinting

NCT02387840
View directory record Official record
Conditions
Neurofibromatosis Type 1, Brain Tumor, Glioma
Interventions
Magnetic Resonance Imaging, Magnetic Resonance Fingerprinting
Device
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
Up to 35 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 12, 2021 · Synced Oct 15, 2026, 4:49 AM EDT
Completed Not applicable Interventional

Whole Brain Radiation Using IMRT for Patients With Brain Metastases

NCT02753790
View directory record Official record
Conditions
Neoplasm Metastasis, Central Nervous System Metastases
Interventions
Intensity Modulated Radiotherapy
Radiation
Lead sponsor
New Mexico Cancer Research Alliance
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated May 22, 2025 · Synced Oct 15, 2026, 4:49 AM EDT
Terminated Phase 2 Interventional Results available

Low-Dose Radiation and Combination Chemotherapy Following Surgery in Children With Newly Diagnosed Medulloblastoma

NCT00031590
View directory record Official record
Conditions
Brain Tumors, Central Nervous System Tumors, Medulloblastoma
Interventions
Cisplatin, Cyclophosphamide, Etoposide, Lomustine, Vincristine, Craniospinal Radiation
Drug · Radiation
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
3 Years to 30 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2011
U.S. locations
3
States / cities
Palo Alto, California • Atlanta, Georgia • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 25, 2019 · Synced Oct 15, 2026, 4:49 AM EDT
Terminated Phase 2 Interventional Results available

Ferumoxytol- and Gadolinium-Labeled MRI in Measuring Tumors Before or After Treatment in Patients With Primary or Metastatic Brain Tumors

NCT00659126
View directory record Official record
Conditions
Metastatic Malignant Neoplasm in the Brain, Primary Brain Neoplasm
Interventions
3 Tesla Magnetic Resonance Imaging, Dynamic Contrast-Enhanced Magnetic Resonance Imaging, Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging, Ferumoxytol, Gadolinium, High Field Strength Magnetic Resonance Imaging, Susceptibility Weighted Imaging
Procedure · Drug
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2020
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 7, 2023 · Synced Oct 15, 2026, 4:49 AM EDT
Completed Phase 1Phase 2 Interventional

Pyrazoloacridine Followed by Radiation Therapy in Treating Adults With Newly Diagnosed Supratentorial Glioblastoma Multiforme

NCT00006355
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
pyrazoloacridine, adjuvant therapy, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2006
U.S. locations
8
States / cities
Birmingham, Alabama • Tampa, Florida • Atlanta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated May 3, 2012 · Synced Oct 15, 2026, 4:49 AM EDT
Not listed Phase 1Phase 2 Interventional

Arsenic Trioxide, Temozolomide, and Radiation Therapy in Treating Patients With Malignant Glioma That Has Been Removed By Surgery

NCT00275067
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
arsenic trioxide, temozolomide, radiation therapy
Drug · Radiation
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2021
U.S. locations
3
States / cities
Chicago, Illinois • Naperville, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 25, 2020 · Synced Oct 15, 2026, 4:49 AM EDT
Completed No phase listed Observational

Evaluation of Factors in Human Brain Tumors

NCT00001171
View directory record Official record
Conditions
Brain Neoplasm, Glioblastoma, Glioma, Pituitary Neoplasm
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
Not listed
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1979 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 15, 2026, 4:49 AM EDT
Completed Phase 2 Interventional Results available

Bortezomib and Dexamethasone Followed by High-Dose Melphalan and Stem Cell Transplantation for Primary (AL) Amyloidosis

NCT01083316
View directory record Official record
Conditions
Amyloidosis
Interventions
Bortezomib, Dexamethasone, Melphalan
Drug
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 25, 2020 · Synced Oct 15, 2026, 4:49 AM EDT
Completed Phase 2 Interventional

Temozolomide in Treating Patients With Newly Diagnosed Anaplastic Oligodendroglioma or Mixed Oligoastrocytoma

NCT00400816
View directory record Official record
Conditions
Central Nervous System Tumors, Brain Tumor
Interventions
temozolomide
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2016
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 18, 2018 · Synced Oct 15, 2026, 4:49 AM EDT
Completed No phase listed Observational

Evaluation of Brain Lesions in HIV-infected Patients for Diagnosis of Primary Central Nervous System Lymphoma

NCT00226304
View directory record Official record
Conditions
HIV Infections, Lymphoma, AIDS-Related
Interventions
Not listed
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 15, 2026, 4:49 AM EDT